Loading...
XOSL
PCIB
Market cap931kUSD
Dec 05, Last price  
0.25NOK
1D
-3.08%
1Q
-37.00%
Jan 2017
-98.19%
IPO
-97.37%
Name

PCI Biotech Holding ASA

Chart & Performance

D1W1MN
XOSL:PCIB chart
P/E
—
P/S
1.40
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.04%
Rev. gr., 5y
-2.15%
Revenues
7m
+125.25%
7,367,0008,612,00010,444,0007,423,000000000000002,990,0006,735,000
Net income
-16m
L-19.19%
-11,375,000-15,015,000-13,940,000-13,749,000-25,259,000-27,608,000-35,840,000-31,922,000-32,184,000-42,841,000-34,780,000-89,252,000-72,636,000-88,480,000-53,743,000-20,315,000-16,417,000
CFO
-14m
L-8.10%
-9,409,000-16,836,000-10,591,000-19,049,000-24,354,000-28,593,000-31,674,000-32,841,000-35,693,000-30,620,000-31,079,000-83,471,000-77,391,000-68,307,000-59,042,000-14,970,000-13,758,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
URL
https://www.pcibiotech.no/
IPO date
Jun 18, 2008
Employees
6
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT